Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Jakesz

Showing results (141-150 of 185) with videos related to

Pageof 19
Sort By:
Cancer Research|November 24, 2001
A genetically engineered influenza A virus with ras-dependent oncolytic propertiesM Bergmann, I Romirer, M Sachet, et al.
British Journal of Cancer|July 1, 1995
Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancerM Fiegl, C Tueni, T Schenk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2009
HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancerS F Schoppmann, D Tamandl, L Roberts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer--10-year resultsM F Gnant, G H Blijham, A Reiner, et al.
Biochemical Pharmacology|January 7, 1998
Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitroR M Mader, A E Sieder, J Braun, et al.
Geburtshilfe Und Frauenheilkunde|January 1, 1996
[Plasminogen activator inhibitor 1 and prognosis in breast carcinoma]K Mayerhofer, J Stolzlechner, S Yildiz, et al.
European Journal of Cancer & Clinical Oncology|July 1, 1988
Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluationB Blöchl-Daum, H G Eichler, H Rainer, et al.
Onkologie|February 1, 1987
Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluationB Blöchl-Daum, H G Eichler, H Rainer, et al.
Anticancer Research|February 24, 2001
Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breastB Gebhard, M Gnant, G Schütz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancerP Birner, G Oberhuber, J Stani, et al.
Pageof 19

Showing results (141-150 of 185) with videos related to

Sort By:
Pageof 19
Cancer Research|November 24, 2001
A genetically engineered influenza A virus with ras-dependent oncolytic propertiesM Bergmann, I Romirer, M Sachet, et al.
British Journal of Cancer|July 1, 1995
Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in breast cancerM Fiegl, C Tueni, T Schenk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2009
HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancerS F Schoppmann, D Tamandl, L Roberts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1993
Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer--10-year resultsM F Gnant, G H Blijham, A Reiner, et al.
Biochemical Pharmacology|January 7, 1998
Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitroR M Mader, A E Sieder, J Braun, et al.
Geburtshilfe Und Frauenheilkunde|January 1, 1996
[Plasminogen activator inhibitor 1 and prognosis in breast carcinoma]K Mayerhofer, J Stolzlechner, S Yildiz, et al.
European Journal of Cancer & Clinical Oncology|July 1, 1988
Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluationB Blöchl-Daum, H G Eichler, H Rainer, et al.
Onkologie|February 1, 1987
Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluationB Blöchl-Daum, H G Eichler, H Rainer, et al.
Anticancer Research|February 24, 2001
Different transendothelial migration behaviour pattern of blood monocytes derived from patients with benign and malignant diseases of the breastB Gebhard, M Gnant, G Schütz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2001
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancerP Birner, G Oberhuber, J Stani, et al.
Pageof 19